KMT2A and leukemia: One of the most attractive features of PROM1/CD133 as a potential therapeutic target derives from the recognition that the gene is a direct target of MLL-AF4 regulation [17, 19, 20], suggesting that in MLLr leukemias PROM1/CD133 expression is tightly linked to the activity of the fusion protein itself.